Endocrinology Month in Review: February 2025

February was a month of significant developments in endocrinology, with notable updates in diabetes management and treatment efficacy. Monlunabant failed to meet its primary endpoint in a Phase 2 trial while promising one-year pilot study results suggested that CELZ-201 could significantly reduce insulin dependency and stabilize hemoglobin A1c (HbA1c) in type 2 diabetes (T2D). Meanwhile, a meta-analysis of over 600 trials highlighted how age and sex may influence the cardioprotective benefits of sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs).